Plasma biomarkers associated with survival and thrombosis in hospitalized COVID-19 patients

  1. David Cabrera-Garcia
  2. Andrea Miltiades
  3. Peter Yim
  4. Samantha Parsons
  5. Katerina Elisman
  6. Mohammad Taghi Mansouri
  7. Gebhard Wagener
  8. Neil L. Harrison

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1007/s12185-022-03437-2
  2. ScreenIT

    SciScore for 10.1101/2021.11.10.21266185: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsConsent: Informed consent was provided by the patients or the surrogates and blood was drawn.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Software and Algorithms
    SentencesResources
    The plasma concentrations of each biomarker were determined using a standard curve, constructed and fit using a 4P logistic regression equation, and the assay values were corrected by the appropriate dilution factor in each case. 2.3. Statistics: All statistical analyses were performed using Prism 8 (GraphPad Software, Inc).
    GraphPad
    suggested: (GraphPad Prism, RRID:SCR_002798)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    Our study has some limitations, such as the modest sample size and the use of a single time point for measurement of the biomarkers. In addition, we suspect that the incidence of thrombosis might be underestimated due to the difficulties in the diagnosis of certain thrombotic events such as microthrombosis [36]. There have been some changes in medication regimens given to patients between the initial and subsequent waves of COVID-19. These might have some effect in the plasma levels of the biomarkers measured in this study and will be the subject of a later report. Nevertheless, the reproducible nature of our findings, and those of others, especially on PAI-1 [16,21] and vWF [26,27] supports the idea that high plasma levels of these biomarkers are a consistent feature of severe COVID-19. Our study provides strong evidence that elevated levels of certain biomarkers such as t-PA, ST2, and vWF, as well as abnormal coagulation [8], may be related to the incidence of thrombosis, renal failure, and might contribute to other longer-term complications in COVID-19 patients. These biomarkers show robust and consistent increases in COVID-19 and can be assessed at the time of admission to non-ICU and ICU settings; they may prove useful as additional predictors of those patients at elevated risk for thrombosis or severe clinical outcomes. In a subsequent report, we will describe effects on these biomarkers and clinical outcomes of a number of medications used in COVID19.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2021.11.10.21266185v1 on medRxiv